SCHEMBL2359272

SCHEMBL2359272

Cc1ccc(NC(=O)c2ccc(C3CCN(C(=O)OC(C)(C)C)CC3)cc2)cc1I

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 1/20 0.55
THRB P10828 3/20 0.49
KMT2A Q03164 2/20 0.48
MEN1 O00255 1/20 0.47
MAPT P10636 7/20 0.47
PTPN2 P17706 1/20 0.47
PTPN1 P18031 1/20 0.47
PTPN6 P29350 1/20 0.47
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
ABL1 P00519 1/20 0.46
RIN1 Q13671 1/20 0.46
IGF1R P08069 1/20 0.46
POLB P06746 2/20 0.44
TP53 P04637 3/20 0.44
KDM4E B2RXH2 1/20 0.44
PKM P14618 1/20 0.44
KDM1A O60341 1/20 0.44
MAOA P21397 1/20 0.44
KDM1B Q8NB78 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2356244 0.84 MAPT (0.57) NAMPTTHRBKMT2AMEN1MAPT
SCHEMBL11889629 0.83 NAMPT (0.64) NAMPTTHRBKMT2AMAPTPTPN2
SCHEMBL2305483 0.81 NAMPT (0.56) NAMPTKMT2AMAPTPTPN2PTPN1
SCHEMBL14454767 0.80 NAMPT (0.59) NAMPTTHRBKMT2AMEN1MAPT
SCHEMBL20354579 0.79 NAMPT (0.58) NAMPTTHRBKMT2AMAPTPTPN2
SCHEMBL2300969 0.78 TBK1 (0.52) KMT2AMEN1MAPTRAB9A
SCHEMBL31027906 0.78 ABL1 (0.57) NAMPTKMT2AMEN1NPC1RAB9A
SCHEMBL2830416 0.78 NAMPT (0.59) NAMPTKMT2AMAPTPTPN2PTPN1
SCHEMBL1199259 0.78 NAMPT (0.57) NAMPTTHRBKMT2AMAPTPTPN2
SCHEMBL15376957 0.77 NAMPT (0.49) NAMPTTHRBKMT2AMAPTPTPN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2350311-B1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS MADRIGAL PHARMACEUTICALS INC (US) 2013-12-25 EP disclosed
US-8324385-B2 Diacylglycerol acyltransferase inhibitors MADRIGAL PHARMACEUTICALS, INC. (US) 2012-12-04 US disclosed
EP-2350311-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS Via Pharmaceuticals, Inc. (US) 2011-08-03 EP disclosed
WO-2010056506-A1 DIACYLGLYCEROL ACLYTRANSFERASE INHIBITORS VIA PHARMACEUTICALS, INC. (US) 2010-05-20 WO disclosed
US-20100113782-A1 Diacylglycerol Acyltransferase Inhibitors MADRIGAL PHARMACEUTICALS, INC. 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113782-A1 Diacylglycerol Acyltransferase Inhibitors DGAT2, DGAT1, MOGAT2 NAMPT 319/4885THRB 974/4885KMT2A 963/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.